Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension
- 538 Downloads
Developing mathematical models to predict changes in ocular bioavailability and pharmacokinetics due to differences in the physicochemical properties of complex topical ophthalmic suspension formulations is important in drug product development and regulatory assessment. Herein, we used published FDA clinical pharmacology review data, in-house, and literature rabbit pharmacokinetic data generated for dexamethasone ophthalmic suspensions to demonstrate how the mechanistic Ocular Compartmental Absorption and Transit model by GastroPlus™ can be used to characterize ocular drug pharmacokinetic performance in rabbits for suspension formulations. This model was used to describe the dose-dependent (0.01 to 0.1%) non-linear pharmacokinetic in ocular tissues and characterize the impact of viscosity (1.67 to 72.9 cP) and particle size (5.5 to 22 μm) on in vivo ocular drug absorption and disposition. Parameter sensitivity analysis (hypothetical suspension particle size: 1 to 10 μm, viscosity: 1 to 100 cP) demonstrated that the interplay between formulation properties and physiological clearance through drainage and tear turnover rates in the pre-corneal compartment drives the ocular drug bioavailability. The quick removal of drug suspended particles from the pre-corneal compartment renders the impact of particle size inconsequential relative to viscosity modification. The in vivo ocular absorption is (1) viscosity non-sensitive when the viscosity is high and the impact of viscosity on the pre-corneal residence time reaches the maximum physiological system capacity or (2) viscosity sensitive when the viscosity is below a certain limit. This study reinforces our understanding of the interplay between physiological factors and ophthalmic formulation physicochemical properties and their impact on in vivo ocular drug PK performance in rabbits.
KEY WORDSbioequivalence dexamethasone ocular PBPK particle size simulation viscosity
Compliance with Ethical Standards
This article reflects the views of the authors and should not be construed to represent FDA’s views or policies.
- 1.Center for Drug Evaluation and Research. Generic drug user fee amendments [Internet]. [cited 2018 Dec 14]. Available from: https://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/default.htm. Accessed 30 Apr 2019.
- 2.US. FDA. Bioavailability and bioequivalence studies for orally administered drug products—general considerations [Internet]. 2003. Available from: https://www.fda.gov/media/87219/download. Accessed 30 Apr 2019.
- 4.Orange book: approved drug products with therapeutic equivalence evaluations [Internet]. [cited 2018 Dec 14]. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/. Accessed 30 Apr 2019.
- 6.US. FDA. Draft Guidance on Dexamethasone; Tobramycin [Internet]. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dexamethasone Tobramycin_ophthalmic suspension NDA 50818 RV Feb 2019.pdf.. Accessed 30 Apr 2019.
- 7.US. FDA. Draft guidance on Nepafenac [Internet]. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nepafenac_ophthalmic suspension 0.1_RLD 0021862_RV12-16.pdf. Accessed 30 Apr 2019.
- 8.US. FDA. Draft guidance on Loteprednol Etabonate [Internet]. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Loteprednol Etabonate_draft_Ophthalmic drops susp_RLD 020583_RCO2-18.pdf. Accessed 30 Apr 2019.
- 16.Lamminsalo M, Taskinen E, Karvinen T, Subrizi A, Murtomäki L, Urtti A, et al. Extended pharmacokinetic model of the rabbit eye for intravitreal and intracameral injections of macromolecules: quantitative analysis of anterior and posterior elimination pathways. Pharm Res. 2018;35(8):153.CrossRefGoogle Scholar
- 17.Hutton-Smith LA, Gaffney EA, Byrne HM, Maini PK, Gadkar K, Mazer NA. Ocular pharmacokinetics of therapeutic antibodies given by intravitreal injection: estimation of retinal permeabilities using a 3-compartment semi-mechanistic model. Mol Pharm. 2017;14(8):2690–6. https://doi.org/10.1021/acs.molpharmaceut.7b00164.CrossRefPubMedGoogle Scholar
- 21.US. FDA. MAXIDEX®- dexamethasone ophthalmic suspension label [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/013422s045lbl.pdf. Accessed 30 Apr 2019.
- 22.US. FDA. TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension) label [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50592slr032_tobradex_lbl.pdf. Accessed 30 Apr 2019.
- 23.US. FDA. TOBRADEX® ST (tobramycin / dexamethasone ophthalmic suspension) label [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050818lbl.pdf. Accessed 30 Apr 2019.
- 24.Chockalingam A, Xu L, Stewart S, Le Merdy M, Tsakalozou E, Fan J, et al. Protocol for evaluation of topical ophthalmic drug products in different compartments of fresh eye tissues in a rabbit model. J Pharmacol Toxicol Methods [Internet] 2018. [cited 2018 Dec 17]; Available from: http://www.sciencedirect.com/science/article/pii/S105687191830697X.
- 25.Matta MK, Narayanasamy S, Thomas CD, Xu L, Stewart S, Chockalingam A, et al. A sensitive UPLC-APCI-MS/MS method for the determination of dexamethasone and its application in an ocular tissue distribution study in rabbits following topical administration. Anal Methods. 2018 May 24;10(20):2307–16.CrossRefGoogle Scholar
- 26.Dexamethasone [Internet]. [cited 2018 Dec 14]. Available from: https://www.drugbank.ca/drugs/DB01234. Accessed 30 Apr 2019.
- 30.Choi Stephanie, Wu Yang, Kozak Darby, Zheng J. Physicochemical characterization of Tobradex and Tobradex ST under physiological conditions. Baltimore; 2017.Google Scholar
- 38.TGA. Australian Public Assessment report for dexamethasone [Internet]. 2016. Available from: https://www.tga.gov.au/sites/default/files/auspar-dexamethasone-161025.docx. Accessed 30 Apr 2019.
- 39.US. FDA. Pharmacology Review(s) NDA 50-818 [Internet]. 2009. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/050818s000pharmr.pdf. Accessed 30 Apr 2019.